- Home
- NVO vs TJX Comparison
NVO vs TJX Comparison
Compare NVO & TJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | TJX |
|---|---|---|
| Founded | 1923 | 1962 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.5B | 177.3B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | NVO | TJX |
|---|---|---|
| Price | $36.53 | $162.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $51.00 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 14.0M | 3.6M |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.48% | 1.19% |
| EPS Growth | N/A | ★ 14.32 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $29,078,407,000.00 |
| Revenue This Year | N/A | $6.75 |
| Revenue Next Year | $3.30 | $5.81 |
| P/E Ratio | ★ $13.60 | $33.12 |
| Revenue Growth | N/A | ★ 6.04 |
| 52 Week Low | $35.12 | $118.59 |
| 52 Week High | $81.44 | $162.68 |
Technical Indicators
Market Signals| Indicator | NVO | TJX |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 59.85 |
| Support Level | $35.85 | $152.69 |
| Resistance Level | $37.44 | $162.63 |
| Average True Range (ATR) | 0.94 | 2.84 |
| MACD | 0.45 | 0.54 |
| Stochastic Oscillator | 36.87 | 93.72 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2025, the company generated roughly $56 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.